ADC Therapeutics SA
Company Profile
Business description
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Contact
Route de la Corniche 3B
Biopole
Epalinges1066
CHET: +41 216530200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
263
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,771.10 | 3.90 | -0.04% |
| CAC 40 | 7,671.29 | 70.95 | -0.92% |
| DAX 40 | 23,385.68 | 313.44 | -1.32% |
| Dow JONES (US) | 42,515.09 | 317.30 | 0.75% |
| FTSE 100 | 8,835.67 | 39.55 | -0.45% |
| HKSE | 23,980.30 | 80.69 | -0.34% |
| NASDAQ | 19,701.21 | 294.39 | 1.52% |
| Nikkei 225 | 38,536.74 | 225.41 | 0.59% |
| NZX 50 Index | 12,639.35 | 50.78 | -0.40% |
| S&P 500 | 6,033.11 | 56.14 | 0.94% |
| S&P/ASX 200 | 8,541.30 | 7.10 | -0.08% |
| SSE Composite Index | 3,387.40 | 1.32 | -0.04% |